Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC)

被引：0
|
作者：
Gadgeel, S. M. [1 ]
Zhang, Q. [2 ]
Lin, H. [3 ]
Fajardo, O. [4 ]
Trinh, H. [5 ]
Arndorfer, S. [6 ]
Kong, S. [7 ]
Rahman, A. [8 ]
Li, S. [9 ]
Archer, V. R. [10 ]
Gainor, J. F. [11 ]
机构：
[1] Henry Ford Hlth Syst, Dept Internal Med, Henry Ford Canc Inst, Detroit, MI USA
[2] Genentech Inc, Product Dev Data Sci, San Francisco, CA USA
[3] Roche Holding Ltd, Roche Product Dev Shanghai, Shanghai, CA, Peoples R China
[4] F Hoffmann La Roche Ltd, Product Dev Data Sci, Basel, Switzerland
[5] Genentech Inc, Product Dev Real World Data Sci, San Francisco, CA USA
[6] Genesis Res, Real World Evidence, Hoboken, NJ USA
[7] Genentech Inc, Biostat, San Francisco, CA USA
[8] Roche Prod Ltd, Product Dev Clin Dev, Welwyn Garden City, Herts, England
[9] Genentech Inc, Product Dev Oncol, San Francisco, CA USA
[10] Roche Prod Ltd, PDC, Welwyn Garden City, Herts, England
[11] Massachusetts Gen Hosp, Ctr Thorac Cancers, Dept Med, Canc Ctr, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2421
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1388P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Real-world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non-small cell lung cancer
    Long, Chaolian
    Li, Kun
    Liu, Zichen
    Zhang, Nana
    Xing, Xuya
    Xu, Liming
    Gai, Fei
    Che, Nanying
    CANCER MEDICINE, 2023, 12 (07): : 7982 - 7991
  • [22] COMPARISON OF REAL-WORLD OUTCOMES BETWEEN A CLINICAL-GENOMICS DATABASE AND OTHER REAL-WORLD DATABASES AMONG IMMUNOTHERAPYTREATED PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)
    Liao, J.
    Zhang, N.
    Das, A.
    VALUE IN HEALTH, 2024, 27 (06) : S367 - S367
  • [23] The Real-World Efficacy and Safety of Anlotinib Treatment for Advanced Non-Small Cell Lung Cancer
    Wang, F.
    Jin, F.
    Wang, S.
    Zhu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S673 - S673
  • [24] Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study
    Zhang, Kun
    Ma, Xiya
    Gao, Hongjun
    Wang, Hong
    Qin, Haifeng
    Yang, Shaoxing
    Liu, Xiaoqing
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 3409 - 3417
  • [25] A Real-World Study: Efficacy and Safety of Anlotinib for Advanced Non-Small Cell Lung Cancer
    Wang, J.
    Yi, T.
    Dong, Y.
    Ran, R.
    Cao, F.
    Li, Y.
    Luo, Z.
    Xu, Y.
    Fu, Y.
    Kuang, L.
    Chen, G.
    Qu, G.
    Yin, Y.
    Li, J.
    Xu, X.
    Chen, Y.
    Song, Q.
    Chu, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1071 - S1071
  • [26] Efficacy and safety of RET-TKI in advanced RET-rearranged non-small cell lung cancer in China: a real-world retrospective chart review
    Lei, Siyu
    Tian, Linyan
    Yang, Lu
    Yang, Yaning
    Li, Junling
    Hu, Xingsheng
    Hao, Xuezhi
    Xu, Haiyan
    Wang, Yan
    BMC CANCER, 2024, 24 (01)
  • [27] Real-world data analysis of PD-L1 expression and overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)
    Staib, J.
    Sudarsanam, S.
    Byfield, S. Dacosta
    Kennedy, C.
    Weiss, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 27 - 27
  • [28] Real-world survival with first-line (1L) chemotherapy in patients (pts) with advanced non-small cell lung cancer (aNSCLC)
    Waterhouse, D.
    Betts, K. A.
    Zhao, J.
    Rao, S.
    Gupte-Singh, K.
    Rutstein, M.
    Higashi, M. K.
    Schwartzberg, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 29 - U99
  • [29] COST OF CARE IN ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) IN THE IMMUNO-ONCOLOGY (10) ERA: A REAL-WORLD ANALYSIS OF EARLY DATA
    Radtchenko, J.
    Korytowsky, B.
    Nwokeji, E.
    Tuell, K.
    Feinberg, B.
    VALUE IN HEALTH, 2018, 21 : S122 - S123
  • [30] Real-World (RW) Predictors of Immuno-Oncology (IO) vs Chemotherapy (C) Use in Advanced Non-Small Cell Lung Cancer (aNSCLC)
    Radtchenko, J.
    Korytowsky, B.
    Nwokeji, E.
    Tue, K.
    Feinberg, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S889 - S889
12345